碩世生物(688399.SH)擬以超募資金投建快速檢測產品項目
格隆匯3月25日丨碩世生物(688399.SH)公佈,公司2020年第三次臨時股東大會審議通過《關於變更部分募投項目實施主體、實施方式以及實施地點的議案》,鑑於目前第三方檢測業務市場規模擴大,為搶抓機遇,提高公司第三方檢測市場佔有份額,公司擬將醫學檢驗場所建設提前實施。
公司擬將超募資金用於碩世生物快速檢測產品項目,項目實施地點位於江蘇省泰州市醫藥高新技術產業開發區,秀水路22號六期標準廠房8-2棟;預計建設期為2年,包括場地裝修、設備購置及安裝以及生產技術人員工資。
項目總投資4813.12萬元,其中裝修費用1150.00萬元,硬件設備購置費用2963.00萬元,生產技術人員工資515.00萬元,基本預備費185.12萬元。擬投入超募資金4813.12萬元,不足部分通過自籌或者自有資金解決。
項目擬擴產的產品將以抗原抗體檢測試劑為主。通過本項目建設,將有效滿足包括各級醫院和門急診檢驗、醫師辦公室、疾控中心、第三方檢測機構、執法機關、個人消費者等對快速檢測產品的需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.